Poland Green Lights Little Green Pharma
Poland Green Lights Little Green Pharma
Little Green Pharma (ASX:LGP) has announced that its Desert Flame high THC (20%) medicinal cannabis flower product has received Marketing Authorisation in Poland. This marks a significant milestone for the company, providing new opportunities in the rapidly growing medicinal cannabis market in Poland.
Little Green Pharma(澳大利亞證券交易所股票代碼：LGP)宣佈，其沙漠火焰高THC(20%)藥用大麻花產品已獲得波蘭營銷授權。這標誌著該公司的一個重要里程碑，為波蘭快速增長的醫用大麻市場提供了新的機會。
In Poland, Marketing Authorisations are the exclusive pathway for the supply of medicinal cannabis products. Presently, there are ten Marketing Authorisations granted for cannabis flower products with THC content in the range of 18-22%. The wholesale prices of medicinal cannabis flower in this category typically range from $7.50 to $9.50 per gram, while retail prices range between $11 and $15 per gram.
在波蘭，銷售授權是供應醫用大麻產品的唯一途徑。目前，有10個大麻花卉產品的銷售許可的含量在18-22%之間。這類藥用大麻花的批發價通常為每克7.50美元至9.50美元，零售價為每克11美元至15美元。
LGP's distribution partner in Poland, Medezin S.p. z.o.o., will be responsible for holding the Marketing Authorisation and distributing the Desert Flame product on a white-label basis during the term of their distribution agreement. Medezin is a highly experienced and large-scale pharmaceutical distributor and is a wholly owned subsidiary of Pelion SA, the largest operator in the Polish and Lithuanian healthcare sectors.
LGP在波蘭的分銷合作夥伴Medezin S.P.Z.O.O.將負責持有營銷授權，並在分銷協定期限內以白標方式分銷Desert Flame產品。Medezin是一家經驗豐富的大型藥品分銷商，是波蘭和立陶宛醫療保健行業最大的運營商Pelion SA的全資子公司。
The initial shipment of Desert Flame high THC medicinal cannabis flower from LGP to Poland is scheduled for October 2023. The company views Poland as a highly promising medicinal cannabis market, with a predicted compound annual growth rate (CAGR) of 16%. Factors contributing to this optimistic outlook include Poland's population of 38 million, an import-only supply regime, GP prescribing capability, and no restrictions on the conditions treatable with cannabis.
從LGP到波蘭的第一批沙漠火焰高THC藥用大麻花計劃於2023年10月發貨。該公司認為波蘭是一個前景看好的醫用大麻市場，預計復合年增長率(CAGR)為16%。促成這一樂觀前景的因素包括波蘭3800萬人口、僅限進口的供應制度、全科醫生處方能力以及對大麻可治療條件的不限制。
LGP's successful acquisition of Marketing Authorisation in Poland demonstrates the company's preparedness to register additional products in Poland and other jurisdictions with similar barriers to entry.
LGP成功地收購了波蘭的營銷授權，表明該公司準備在波蘭和其他具有類似進入壁壘的司法管轄區註冊更多產品。
With this latest development, LGP reinforces its position as a significant global exporter of medicinal cannabis. The company's export-led sales strategy is further validated, positioning LGP to capitalize on the increasing demand for medicinal cannabis products in Europe.
隨著這一最新發展，LGP鞏固了其作為全球主要醫用大麻出口商的地位。該公司的出口導向型銷售戰略得到進一步驗證，使LGP能夠利用歐洲對醫用大麻產品日益增長的需求。
The grant of Marketing Authorisation in Poland presents a notable opportunity for Little Green Pharma Ltd, expanding its presence in a promising market and enhancing its reputation as a key player in the global medicinal cannabis industry.
在波蘭的營銷授權為Little Green Pharma Ltd提供了一個重要的機會，擴大了其在一個前景廣闊的市場的存在，並提高了其作為全球醫用大麻行業關鍵參與者的聲譽。
譯文內容由第三人軟體翻譯。